Pfizer’s COVID-19 Vaccine Shows Mild-To-Moderate Side Effects in Phase 3 Clinical Trial
By HospiMedica International staff writers Posted on 17 Sep 2020 |
Image: Pfizer’s COVID-19 Vaccine Shows Mild-To-Moderate Side Effects in Phase 3 Clinical Trial (Photo courtesy of Pfizer)
Pfizer Inc. (New York, NY, USA) has stated that participants in an ongoing late-stage study who were given either its experimental COVID-19 vaccine or a placebo were showing mild-to-moderate side effects.
Pfizer is developing the investigational vaccine candidate in partnership with Biopharmaceutical New Technologies (BioNTech Mainz, Germany). The experimental COVID-19 vaccine is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities.
Pfizer is conducting a placebo-controlled trial to evaluate the safety and efficacy of the COVID-19 vaccine in up to 44,000 participants who will receive either the vaccine or placebo. During an investor conference call, Pfizer executives confirmed that it had enrolled over 29,000 people for the trial and had given a second dose of the experimental COVID-19 vaccine to more than 12,000 study participants. The COVID-19 vaccine had demonstrated a "mostly mild to moderate” safety profile, with rare instances of severe or grade 4 side effects. According to the company, the study participants who had been given only the first dose of COVID-19 vaccine experienced mainly fatigue and headache, with others reported muscle pain, diarrhea, chills and joint pain.
Pfizer has assured that it continues to scrutinize the safety and tolerability of the vaccine in its study. The company also said that an independent data monitoring committee could recommend halting the study any time, although it had not done so until now.
Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies
Pfizer is developing the investigational vaccine candidate in partnership with Biopharmaceutical New Technologies (BioNTech Mainz, Germany). The experimental COVID-19 vaccine is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities.
Pfizer is conducting a placebo-controlled trial to evaluate the safety and efficacy of the COVID-19 vaccine in up to 44,000 participants who will receive either the vaccine or placebo. During an investor conference call, Pfizer executives confirmed that it had enrolled over 29,000 people for the trial and had given a second dose of the experimental COVID-19 vaccine to more than 12,000 study participants. The COVID-19 vaccine had demonstrated a "mostly mild to moderate” safety profile, with rare instances of severe or grade 4 side effects. According to the company, the study participants who had been given only the first dose of COVID-19 vaccine experienced mainly fatigue and headache, with others reported muscle pain, diarrhea, chills and joint pain.
Pfizer has assured that it continues to scrutinize the safety and tolerability of the vaccine in its study. The company also said that an independent data monitoring committee could recommend halting the study any time, although it had not done so until now.
Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans